ARCA biopharma Net Tangible Assets

ARCA biopharma (ABIO) currently reports a net tangible assets of $1.1B as of June 2026. That compares with $340M in the prior-year period — up 224.3% year over year. Use the charts on this page to explore ARCA biopharma's net tangible assets history and peer comparisons.

ARCA biopharma's net tangible assets increased from $340M to $1.1B — a 224.3% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

ARCA biopharma reported $1.1B in net tangible assets as of June 2026. That compares with $340M in the prior-year period — up 224.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net tangible assets of $1.1B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for ARCA biopharma, and consider following ABIO for alerts when major investors trade the stock.

ARCA biopharma is classified in the Healthcare sector. On net tangible assets, it currently shows $1.1B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ABIO with unrelated industries.